Afinity Ultra Pure Fish Oil (Rheumatoid Arthritis Relief)
Afinity Ultra Pure Fish Oil (Rheumatoid Arthritis Relief), NPN 80035151: natural health product licensed in Canada. Medicinal ingredients: Huile de poisson.
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Huile de poisson Source : Engraulidae - en entier Potency : 253 mg Docosahexaenoic acid | 1.1 g | Not calculated |
| Huile de poisson Source : Engraulidae - en entier Potency : 495 mg Eicosapentaenoic acid | Not specified | Not calculated |
Non-medicinal ingredients
dl-alpha tocophérol, Eau purifiée, Gélatine, Glycérine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 2 Capsule ; maximum: 3 Capsule | 2 Tous les jours |
Uses authorised in Canada
In conjunction with conventional therapy, helps to reduce the pain of rheumatoid arthritis in adults.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contra-Indications
Not recommended for those with known hypersensitivity and/or allergies to any of the ingredients.
Product record
- Other names
- Afinity Ultra Pure Fish Oil (Joint Care), Afinity Ultra Pure Fish Oil, Afinity Arthritic Care, GenBioChem Ultra-Pure Fish Oil (Joint Care), GenBioChem Ultra-Pure Fish Oil (Rheumatoid Arthritis Relief), GenBioChem Ultra-Pure Fish Oil, Arthritic Care
- Licence holder
- Natural RF Life Sciences Inc.
- NPN or DIN-HM
- 80035151
- Status
- Active licence
- Licence date
- 30 August 2012
- Revision date
- 5 March 2025
- Form
- Capsule, molle
- Route of administration
- Orale
- Application type
- Officinale
Source
Official Health Canada record, licence 80035151
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Huile de poisson
Read the warning, when it applies and the studies cited
FISH OIL
Route of administration: Oral
Cautions and warnings
Condition of application: Pain of rheumatoid arthritis.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
Condition of application: Healthy mood balance.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Afinity Ultra Pure Fish Oil (Rheumatoid Arthritis Relief) (Natural RF Life Sciences Inc.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80035151-afinity-ultra-pure-fish-oil-rheumatoid-arthritis-relief, updated 5 March 2025.